These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 19270023)

  • 1. Shingles vaccination is likely to be cost effective at age 65 or 70.
    Dobson R
    BMJ; 2009 Mar; 338():b944. PubMed ID: 19270023
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost-effectiveness of vaccination against herpes zoster in adults aged over 60 years in Belgium.
    Bilcke J; Marais C; Ogunjimi B; Willem L; Hens N; Beutels P
    Vaccine; 2012 Jan; 30(3):675-84. PubMed ID: 22120193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of vaccination of the elderly against herpes zoster in The Netherlands.
    de Boer PT; Pouwels KB; Cox JM; Hak E; Wilschut JC; Postma MJ
    Vaccine; 2013 Feb; 31(9):1276-83. PubMed ID: 23306360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Q: Who should receive the shingles vaccine?
    Singh A; Englund K
    Cleve Clin J Med; 2009 Jan; 76(1):45-8. PubMed ID: 19122110
    [No Abstract]   [Full Text] [Related]  

  • 5. [Shingles vaccine: which recommendations in 2014?].
    Vionnet J; Hart K; Spertini F
    Rev Med Suisse; 2014 Apr; 10(426):869-72, 874-5. PubMed ID: 24834646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of vaccination against herpes zoster and postherpetic neuralgia: a critical review.
    Kawai K; Preaud E; Baron-Papillon F; Largeron N; Acosta CJ
    Vaccine; 2014 Mar; 32(15):1645-53. PubMed ID: 24534737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Importance of vaccination against herpes zoster.
    Evans DL;
    J Am Osteopath Assoc; 2010 Feb; 110(2 Suppl 1):S14-20. PubMed ID: 20207984
    [No Abstract]   [Full Text] [Related]  

  • 8. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
    Pellissier JM; Brisson M; Levin MJ
    Vaccine; 2007 Nov; 25(49):8326-37. PubMed ID: 17980938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interpretation of results of the cost-effectiveness analysis reported by Pellissier et al. on October 2007.
    Najafzadeh M; Sadatsafavi M; Marra CA
    Vaccine; 2008 Sep; 26(41):5244; author reply 5245. PubMed ID: 18619510
    [No Abstract]   [Full Text] [Related]  

  • 10. Cost-effectiveness of herpes zoster vaccine: flawed assumptions regarding efficacy against postherpetic neuralgia.
    Brisson M; Pellissier JM; Levin MJ
    Clin Infect Dis; 2007 Dec; 45(11):1527-9. PubMed ID: 17990240
    [No Abstract]   [Full Text] [Related]  

  • 11. Cost-effectiveness of a herpes zoster vaccination program among the French elderly people.
    Belchior E; Lévy-Bruhl D; Le Strat Y; Herida M
    Hum Vaccin Immunother; 2016 Sep; 12(9):2378-82. PubMed ID: 27484158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors affecting an economic model for zoster vaccination.
    Fattore G
    Herpes; 2007 Sep; 14 Suppl 2():52-5. PubMed ID: 17939898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preventing herpes zoster through vaccination.
    Gelb LD
    Ophthalmology; 2008 Feb; 115(2 Suppl):S35-8. PubMed ID: 18243932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Why should older adults receive the shingles vaccine?
    Harkness TL
    J Gerontol Nurs; 2010 Oct; 36(10):51-5. PubMed ID: 20506935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost Effectiveness of a Shingles Vaccine Booster for Currently Vaccinated Adults in the U.S.
    Le P; Rothberg MB
    Am J Prev Med; 2017 Dec; 53(6):829-836. PubMed ID: 29153126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and economic impact of herpes zoster vaccination in elderly in Italy.
    Boccalini S; Alicino C; Martinelli D; Bechini A; Tiscione E; Pellizzari B; Prato R; Icardi G; Iannazzo S; Bonanni P
    Hum Vaccin Immunother; 2017 Feb; 13(2):405-411. PubMed ID: 27925856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Herpes zoster vaccination: benefits and barriers.
    Komara FA
    J Am Osteopath Assoc; 2009 Jun; 109(6 Suppl 2):S22-4. PubMed ID: 19553633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The burden of Herpes Zoster and its complications in Poland in according to the age.
    Albrecht P; Patrzałek M; Goryński P
    Przegl Epidemiol; 2015; 69(4):693-7, 841-3. PubMed ID: 27139346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is herpes zoster vaccination likely to be cost-effective in Canada?
    Peden AD; Strobel SB; Forget EL
    Can J Public Health; 2014 May; 105(4):e287-95. PubMed ID: 25166132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Zoster vaccine live.
    Kockler DR; McCarthy MW
    Pharmacotherapy; 2007 Jul; 27(7):1013-9. PubMed ID: 17594207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.